These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29119445)

  • 1. Guidelines for Bacteriophage Product Certification.
    Fauconnier A
    Methods Mol Biol; 2018; 1693():253-268. PubMed ID: 29119445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phage Therapy Regulation: From Night to Dawn.
    Fauconnier A
    Viruses; 2019 Apr; 11(4):. PubMed ID: 30999559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine.
    Verbeken G; Pirnay JP; De Vos D; Jennes S; Zizi M; Lavigne R; Casteels M; Huys I
    Arch Immunol Ther Exp (Warsz); 2012 Jun; 60(3):161-72. PubMed ID: 22527355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriophage Production in Compliance with Regulatory Requirements.
    Pirnay JP; Merabishvili M; Van Raemdonck H; De Vos D; Verbeken G
    Methods Mol Biol; 2018; 1693():233-252. PubMed ID: 29119444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magistral Phage Preparations: Is This the Model for Everyone?
    Pirnay JP; Verbeken G
    Clin Infect Dis; 2023 Nov; 77(Suppl 5):S360-S369. PubMed ID: 37932120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacteriophage Production in Compliance with Regulatory Requirements.
    Pirnay JP; Merabishvili M; De Vos D; Verbeken G
    Methods Mol Biol; 2024; 2734():89-115. PubMed ID: 38066364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework.
    Verbeken G; Huys I; De Vos D; De Coninck A; Roseeuw D; Kets E; Vanderkelen A; Draye JP; Rose T; Jennes S; Ceulemans C; Pirnay JP
    FEMS Microbiol Lett; 2016 Feb; 363(4):. PubMed ID: 26678555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Call for a dedicated European legal framework for bacteriophage therapy.
    Verbeken G; Pirnay JP; Lavigne R; Jennes S; De Vos D; Casteels M; Huys I
    Arch Immunol Ther Exp (Warsz); 2014 Apr; 62(2):117-29. PubMed ID: 24500660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Magistral Phage.
    Pirnay JP; Verbeken G; Ceyssens PJ; Huys I; De Vos D; Ameloot C; Fauconnier A
    Viruses; 2018 Feb; 10(2):. PubMed ID: 29415431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of regulated clinical trials in the development of bacteriophage therapeutics.
    Parracho HM; Burrowes BH; Enright MC; McConville ML; Harper DR
    J Mol Genet Med; 2012; 6():279-86. PubMed ID: 22872803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Veterinary autogenous vaccines.
    Hera A; Bures J
    Dev Biol (Basel); 2004; 117():19-25. PubMed ID: 15597612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phage cocktails and the future of phage therapy.
    Chan BK; Abedon ST; Loc-Carrillo C
    Future Microbiol; 2013 Jun; 8(6):769-83. PubMed ID: 23701332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Regulatory requirements regarding cell-based medicinal products for human and veterinary use - a comparison].
    Kuhlmann-Gottke J; Duchow K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1299-305. PubMed ID: 26369765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory Acceptance of Alternative Methods in the Development and Approval of Pharmaceuticals.
    Beken S; Kasper P; van der Laan JW
    Adv Exp Med Biol; 2016; 856():33-64. PubMed ID: 27671719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality and safety requirements for sustainable phage therapy products.
    Pirnay JP; Blasdel BG; Bretaudeau L; Buckling A; Chanishvili N; Clark JR; Corte-Real S; Debarbieux L; Dublanchet A; De Vos D; Gabard J; Garcia M; Goderdzishvili M; Górski A; Hardcastle J; Huys I; Kutter E; Lavigne R; Merabishvili M; Olchawa E; Parikka KJ; Patey O; Pouilot F; Resch G; Rohde C; Scheres J; Skurnik M; Vaneechoutte M; Van Parys L; Verbeken G; Zizi M; Van den Eede G
    Pharm Res; 2015 Jul; 32(7):2173-9. PubMed ID: 25585954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advanced therapy: from European regulatory framework to national regulatory framework].
    Lucas-Samuel S
    Transfus Clin Biol; 2013 May; 20(2):221-4. PubMed ID: 23517820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From medical tradition to traditional medicine: A Tibetan formula in the European framework.
    Schwabl H; Vennos C
    J Ethnopharmacol; 2015 Jun; 167():108-14. PubMed ID: 25446636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction to EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD).
    Chiti A
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2174. PubMed ID: 25143074
    [No Abstract]   [Full Text] [Related]  

  • 19. Veterinary Products Committee working group report on feline and canine vaccination.
    Gaskell RM; Gettinby G; Graham SJ; Skilton D
    Vet Rec; 2002 Feb; 150(5):126-34. PubMed ID: 11871665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phage therapy: a reappraisal of bacteriophages as antibiotics.
    Inal JM
    Arch Immunol Ther Exp (Warsz); 2003; 51(4):237-44. PubMed ID: 12956433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.